Epocrates targets OTCs with reference module

Share this article:
Epocrates targets OTCs with reference module
Epocrates targets OTCs with reference module
Epocrates introduced a new OTC drug module that will allow clinicians to access the latest information for hundreds of brand name OTC drugs from their iPhone, BlackBerry, Palm or Windows device.

Officials at the San Mateo, CA-based company note that OTC products with multiple active ingredients are very common since patients often have many symptoms to treat at once. The OTC reference module will allow physicians and pharmacists to identify specific ingredients in combination products, such as for cough and cold. For instance, an antihistamine could cause additional drowsiness or interact with blood pressure medicines.

A physician using Epocrates software could quickly find the single offending agent causing a product's contraindication, adverse reaction or drug interactions and identify an alternative.

Health providers may also use the software to uncover: drug interactions between OTC and prescription medications; safe products for pregnant women and sugar-free products for diabetics; products covered by Medicaid and select health plans for eligible patients; and medications by class such as analgesics or expectorants (cough syrups). 

Epocrates is a provider of clinical information and decision support tools to healthcare professionals and currently has more than 800,000 active subscribers worldwide, including more than one in three US physicians and 40% of US medical students.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...